This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.


The times they are a-changin’: the Cachexia Conference goes annual

Stephan von Haehling*, Stefan D. Anker

Article first published online: 22 FEB 2016

DOI: 10.1002/jcsm.12110

How to Cite

von Haehling, S., and Anker, S. D. (2016) The times they are a-changin’: the Cachexia Conference goes annual. Journal of Cachexia, Sarcopenia and Muscle, doi: 10.1002/jcsm.12110.

Author Information

Institute of Innovative Clinical Trial, Department of Cardiology and Pneumology, University of Göttingen Medical School, Göttingen, Germany

*Correspondence to: Dr Stephan von Haehling, Institute of Innovative Clinical Trials, Department of Cardiology and Pneumology, University of Göttingen Medical School, Robert-Koch-Strasse 40, D - 37075 Göttingen, Germany: Tel.: +49 551 39 20911; Fax: +49 551 39 20918, Email: stephan.von.haehling@web.de

The field of cachexia and muscle wasting research has started to move, slowly but steadily, and large and small companies alike are increasing their efforts into the development of new drug therapies for cachexia, sarcopenia and frailty. Recent research has focused on novel screening tools[1] and biomarker research to enable an early diagnosis of wasting,[2, 3] but also on the pathophysiological understanding of the wasting process[4, 5] nutrition,[6, 7] exercise, particularly in cachectic cancer patients,[8-10] and novel therapeutic approaches.[11-13] Even though the pathophysiological understanding is making rapid progress – if not by the minute or day, then by the week for sure – recent phase III trials have failed unfortunately to translate gain in muscle mass into gain in muscle function, i.e. more exercise capacity or strength or better stair climbing power.

The Cachexia Conference, closely affiliated with this journal and the Society of Sarcopenia, Cachexia and Wasting Disorders (SCWD), until recently held ist conferences only every other year in a different location. The Cachexia Conferences closely follow the rapid progress in the field of cachexia research. Therefore, as of this coming December, the conference will be held annually. Indeed, the 9th Cachexia Conference is due to take place on December 10-11, 2016, in Berlin, Germany. Berlin is a city that is changing as quickly as the field of cachexia research. Following the lines of Bob Dylan's song The Times They Are A-changin’, we invite researchers to come to Berlin to share their enthusiam and insight:

‘Come senators, congressmen

Please heed the call

Don't stand in the doorway

Don't block up the hall

For he that gets hurt

Will be he who has stalled

There's a battle outside

And it is ragin'.

It'll soon shake your windows

And rattle your walls

For the times they are a-changin'.

Bob Dylan

We would like to make the conference a very hands-on meeting with (likely) no parallel sessions and a programme made by the audience. We hereby call for your session proposals to be send to Mrs Monika Diek at the SCWD office (conference2016@cachexia.info). Please do so by 15th April, 2016.

As we start to go annual, we will still hold a big Cachexia Conference for 3 full days (as done in Paris) every 2 years, and every other 2 years the meeting is a 2-day affair. As the field gains momentum, we may change this in the future, but fort he time being this seems tob e prudent.

So please, safe the date and come to Berlin on 10/11 December, 2016. And send us your session proposals.


The authors of this manuscript certify that they comply with the principles of ethical publishing in the Journal of Cachexia, Sarcopenia, and Muscle 2015.[14]


1Morley JE, Cao L. Rapid screening for sarcopenia. J Cachexia Sarcopenia Muscle 2015;6:312314.2Drescher C, Konishi M, Ebner N, Springer J. Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment. J Cachexia Sarcopenia Muscle 2015;6:303311.3Calvani R, Marini F, Cesari M, Tosato M, Anker SD, von Haehling S, et al. SPRINTT consortium. Biomarkers for physical frailty and sarcopenia: state of the science and future developments. J Cachexia Sarcopenia Muscle 2015;6:278286.4Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle 2015;6:287302.5von Haehling S. The wasting continuum in heart failure: from sarcopenia to cachexia. Proc Nutr Soc 2015;74:367377.6Gu W, Zhang G, Sun L, Ma Q, Cheng Y, Zhang H, et al. Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma. J Cachexia Sarcopenia Muscle 2015;6:222230.7van Dijk DP, van de Poll MC, Moses AG, Preston T, Olde Damink SW, Rensen SS, et al. Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients. J Cachexia Sarcopenia Muscle 2015;6:212221.8Grande AJ, Silva V, Maddocks M. Exercise for cancer cachexia in adults: Executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle 2015;6:208211.9Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle 2015;6:115124.10Jones LW, Douglas PS, Eves ND, Marcom PK, Kraus WE, Herndon JE 2nd, et al. Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer. BMC Cancer 2010;10:531.11Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 2013;21:129137.12Fearon K, Argiles JM, Baracos VE, Bernabei R, Coats A, Crawford J, et al. Request for regulatory guidance for cancer cachexia intervention trials. J Cachexia Sarcopenia Muscle 2015;6:272274.13Leese PT, Trang JM, Blum RA, de Groot E. An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin. Clin Pharmacol Drug Dev 2015;4:112120.14von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015. J Cachexia Sarcopenia Muscle 2015;6:315316.